Eicosanoids are 20-carbon fatty acids, where the usual focus is the polyunsaturated analogue arachidonic acid and its metabolites. Arachidonic acid is thought primarily to derive from phospholipase A2 action on membrane phosphatidylcholine, and may be re-cycled to form phospholipid through conjugation with coenzyme A and subsequently glycerol derivatives. Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450-like epoxygenases, particularly CYP2J2. Isoprostanes are structural analogues of the prostanoids (hence the nomenclature D-, E-, F-isoprostanes and isothromboxanes), which are produced in the presence of elevated free radicals in a non-enzymatic manner, leading to suggestions for their use as biomarkers of oxidative stress. Molecular targets for their action have yet to be defined.

* Key recommended reading is highlighted with an asterisk

* Ackermann JA, Hofheinz K, Zaiss MM, Krönke G. (2017) The double-edged role of 12/15-lipoxygenase during inflammation and immunity. Biochim Biophys Acta, 1862 (4): 371-381. [PMID:27480217]

Aïd S, Bosetti F. (2011) Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie, 93 (1): 46-51. [PMID:20868723]

Cathcart MC, O'Byrne KJ, Reynolds JV, O'Sullivan J, Pidgeon GP. (2012) COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta, 1825 (1): 49-63. [PMID:22015819]

Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD. (2014) Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol, 88 (4): 565-72. [PMID:24434190]

Davidson J, Rotondo D, Rizzo MT, Leaver HA. (2012) Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism. Br J Pharmacol, 166 (4): 1193-210. [PMID:22364602]

Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. (2011) Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res, 50 (1): 115-31. [PMID:20970452]

Durand T, Bultel-Poncé V, Guy A, El Fangour S, Rossi JC, Galano JM. (2011) Isoprostanes and phytoprostanes: Bioactive lipids. Biochimie, 93 (1): 52-60. [PMID:20594988]

Floyd CN, Ferro A. (2014) Mechanisms of aspirin resistance. Pharmacol Ther, 141 (1): 69-78. [PMID:23993980]

Félétou M, Huang Y, Vanhoutte PM. (2011) Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol, 164 (3): 894-912. [PMID:21323907]

Grosser T, Ricciotti E, FitzGerald GA. (2017) The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. Trends Pharmacol Sci, 38 (8): 733-748. [PMID:28651847]

* Haeggström JZ. (2018) Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest, 128 (7): 2680-2690. [PMID:30108195]

Haeggström JZ, Funk CD. (2011) Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev, 111 (10): 5866-98. [PMID:21936577]

Horn T, Adel S, Schumann R, Sur S, Kakularam KR, Polamarasetty A, Redanna P, Kuhn H, Heydeck D. (2015) Evolutionary aspects of lipoxygenases and genetic diversity of human leukotriene signaling. Prog Lipid Res, 57: 13-39. [PMID:25435097]

* Häfner AK, Kahnt AS, Steinhilber D. (2019) Beyond leukotriene formation-The noncanonical functions of 5-lipoxygenase. Prostaglandins Other Lipid Mediat, 142: 24-32. [PMID:30930090]

* Imig JD. (2020) Eicosanoid blood vessel regulation in physiological and pathological states. Clin Sci (Lond), 134 (20): 2707-2727. [PMID:33095237]

Joshi YB, Giannopoulos PF, Praticò D. (2015) The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease. Trends Pharmacol Sci, 36 (3): 181-186. [PMID:25708815]

Koeberle A, Werz O. (2015) Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochem Pharmacol, 98 (1): 1-15. [PMID:26123522]

Korotkova M, Jakobsson PJ. (2014) Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol, 10 (4): 229-41. [PMID:24514915]

Krieg P, Fürstenberger G. (2014) The role of lipoxygenases in epidermis. Biochim Biophys Acta, 1841 (3): 390-400. [PMID:23954555]

Kuhn H, Banthiya S, van Leyen K. (2015) Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta, 1851 (4): 308-30. [PMID:25316652]

Majed BH, Khalil RA. (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev, 64 (3): 540-82. [PMID:22679221]

* Mitchell JA, Kirkby NS. (2019) Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol, 176 (8): 1038-1050. [PMID:29468666]

Muñoz-Garcia A, Thomas CP, Keeney DS, Zheng Y, Brash AR. (2014) The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier. Biochim Biophys Acta, 1841 (3): 401-8. [PMID:24021977]

O'Banion MK. (2010) Prostaglandin E2 synthases in neurologic homeostasis and disease. Prostaglandins Other Lipid Mediat, 91 (3-4): 113-7. [PMID:19393332]

* Orafaie A, Mousavian M, Orafai H, Sadeghian H. (2020) An overview of lipoxygenase inhibitors with approach of in vivo studies. Prostaglandins Other Lipid Mediat, 148: 106411. [PMID:31953016]

Patrignani P, Patrono C. (2015) Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochim Biophys Acta, 1851 (4): 422-32. [PMID:25263946]

Rodríguez M, Domingo E, Municio C, Alvarez Y, Hugo E, Fernández N, Sánchez Crespo M. (2014) Polarization of the innate immune response by prostaglandin E2: a puzzle of receptors and signals. Mol Pharmacol, 85 (1): 187-97. [PMID:24170779]

Rouzer CA, Marnett LJ. (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev, 111 (10): 5899-921. [PMID:21923193]

Rådmark O, Werz O, Steinhilber D, Samuelsson B. (2015) 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta, 1851 (4): 331-9. [PMID:25152163]

Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. (2012) Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med, 18 (4): 233-43. [PMID:22425675]

Saper CB, Romanovsky AA, Scammell TE. (2012) Neural circuitry engaged by prostaglandins during the sickness syndrome. Nat Neurosci, 15 (8): 1088-95. [PMID:22837039]

Sasaki Y, Ochiai T, Takamura M, Kondo Y, Yokoyama C, Hara S. (2017) Role of prostacyclin synthase in carcinogenesis. Prostaglandins Other Lipid Mediat, 133: 49-52. [PMID:28506876]

* Seo MJ, Oh DK. (2017) Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis. Prog Lipid Res, 66: 50-68. [PMID:28392405]

Smith WL, Urade Y, Jakobsson PJ. (2011) Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev, 111 (10): 5821-65. [PMID:21942677]

Sostres C, Lanas A. (2011) Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol, 8 (7): 385-94. [PMID:21647198]

Tai HH, Chi X, Tong M. (2011) Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins Other Lipid Mediat, 96 (1-4): 37-40. [PMID:21763448]

* Thulasingam M, Haeggström JZ. (2020) Integral Membrane Enzymes in Eicosanoid Metabolism: Structures, Mechanisms and Inhibitor Design. J Mol Biol, 432 (18): 4999-5022. [PMID:32745470]

Vitale P, Panella A, Scilimati A, Perrone MG. (2016) COX-1 Inhibitors: Beyond Structure Toward Therapy. Med Res Rev, 36 (4): 641-71. [PMID:27111555]

* Xu D, Cai J, Wan ZK, Gao H, Sun Y. (2021) Pathophysiological role of prostaglandin E synthases in liver diseases. Prostaglandins Other Lipid Mediat, 154: 106552. [PMID:33930567]

Angelo A. Izzo Department of Pharmacy School of Medicine and Surgery University of Naples Federico II Naples, Italy